Tags

Type your tag names separated by a space and hit enter

Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis.
Clin Immunol. 2009 Feb; 130(2):145-50.CI

Abstract

Matrix metalloproteinases (MMPs) and tissue inhibitors (TIMPs) play a key role in the pathogenesis of multiple sclerosis (MS) and have been proposed as biomarkers of response to therapy. We investigated serum levels of several MMPs and TIMPs in 43 relapsing-remitting MS (RRMS) patients undergoing interferon-beta (IFN-b) treatment and classified as responders and non-responders based on clinical criteria. Levels of MMP-2, MMP-7, MMP-9, TIMP-1 and TIMP-2 were determined by ELISA before treatment and after 3, 6, 12, and 24 months of therapy. Neutralizing antibodies were determined by the myxovirus A induction bioassay. Treatment with IFN-b induced changes in levels of MMP-9 and TIMP-1. In contrast to non-responders, IFN-b resulted in an early and sustained increase in TIMP-1 levels in MS patients who showed clinical response to IFN-b. The early and sustained increase in TIMP-1 levels could be a marker of the response to IFN-b during the first 2 years of treatment.

Authors+Show Affiliations

Unitat de Neuroimmunologia Clínica, CEM-Cat, Hospital Universitari Vall d'Hebron (HUVH), Barcelona, Spain. mcomabel@ir.vhebron.netNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18945642

Citation

Comabella, Manuel, et al. "Changes in Matrix Metalloproteinases and Their Inhibitors During Interferon-beta Treatment in Multiple Sclerosis." Clinical Immunology (Orlando, Fla.), vol. 130, no. 2, 2009, pp. 145-50.
Comabella M, Río J, Espejo C, et al. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clin Immunol. 2009;130(2):145-50.
Comabella, M., Río, J., Espejo, C., Ruiz de Villa, M., Al-Zayat, H., Nos, C., Deisenhammer, F., Baranzini, S. E., Nonell, L., López, C., Julià, E., Oksenberg, J. R., & Montalban, X. (2009). Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clinical Immunology (Orlando, Fla.), 130(2), 145-50. https://doi.org/10.1016/j.clim.2008.09.010
Comabella M, et al. Changes in Matrix Metalloproteinases and Their Inhibitors During Interferon-beta Treatment in Multiple Sclerosis. Clin Immunol. 2009;130(2):145-50. PubMed PMID: 18945642.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. AU - Comabella,Manuel, AU - Río,Jordi, AU - Espejo,Carmen, AU - Ruiz de Villa,Mamen, AU - Al-Zayat,Hammad, AU - Nos,Carlos, AU - Deisenhammer,Florian, AU - Baranzini,Sergio E, AU - Nonell,Lara, AU - López,Cristina, AU - Julià,Eva, AU - Oksenberg,Jorge R, AU - Montalban,Xavier, Y1 - 2008/10/21/ PY - 2008/05/23/received PY - 2008/07/28/revised PY - 2008/09/03/accepted PY - 2008/10/24/pubmed PY - 2009/1/28/medline PY - 2008/10/24/entrez SP - 145 EP - 50 JF - Clinical immunology (Orlando, Fla.) JO - Clin Immunol VL - 130 IS - 2 N2 - Matrix metalloproteinases (MMPs) and tissue inhibitors (TIMPs) play a key role in the pathogenesis of multiple sclerosis (MS) and have been proposed as biomarkers of response to therapy. We investigated serum levels of several MMPs and TIMPs in 43 relapsing-remitting MS (RRMS) patients undergoing interferon-beta (IFN-b) treatment and classified as responders and non-responders based on clinical criteria. Levels of MMP-2, MMP-7, MMP-9, TIMP-1 and TIMP-2 were determined by ELISA before treatment and after 3, 6, 12, and 24 months of therapy. Neutralizing antibodies were determined by the myxovirus A induction bioassay. Treatment with IFN-b induced changes in levels of MMP-9 and TIMP-1. In contrast to non-responders, IFN-b resulted in an early and sustained increase in TIMP-1 levels in MS patients who showed clinical response to IFN-b. The early and sustained increase in TIMP-1 levels could be a marker of the response to IFN-b during the first 2 years of treatment. SN - 1521-7035 UR - https://www.unboundmedicine.com/medline/citation/18945642/Changes_in_matrix_metalloproteinases_and_their_inhibitors_during_interferon_beta_treatment_in_multiple_sclerosis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1521-6616(08)00821-8 DB - PRIME DP - Unbound Medicine ER -